NCT05177133 (AuspiCiOus) is a Phase 2 clinical trial of Capecitabine in Gastric Adenocarcinoma, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Who is sponsoring NCT05177133?

NCT05177133 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

What drugs are being tested in NCT05177133?

Interventions in NCT05177133: Capecitabine, Oxaliplatin, Retifanlimab.

What condition does NCT05177133 study?

NCT05177133 studies Gastric Adenocarcinoma, Esophageal Adenocarcinoma.

Is NCT05177133 still recruiting?

NCT05177133 is currently recruiting now. Last updated 2 August 2024.

Last reviewed 2024-08-02 · How we verify

NCT05177133: AuspiCiOus

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)

Recruiting now Phase 2 Last updated 2 August 2024

What this trial tests

Phase 2 trial testing Capecitabine in Gastric Adenocarcinoma in 25 participants. Currently enrolling.

Timeline

5 November 2021

Primary endpoint
1 May 2025

4 November 2029

Quick facts

Lead sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	5 November 2021
Primary completion	1 May 2025
Estimated completion	4 November 2029
Sites	8 locations across Netherlands

Drugs / interventions tested

Capecitabine (capecitabine) — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →
Retifanlimab (RETIFANLIMAB) — full drug profile →

Conditions studied

Gastric Adenocarcinoma — all drugs for Gastric Adenocarcinoma →
Esophageal Adenocarcinoma — all drugs for Esophageal Adenocarcinoma →

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full company profile →

Who can join

18 and older, any sex, with Gastric Adenocarcinoma or Esophageal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the effects of the combination of two chemotherapies followed by immunostimulants on the interferon gamma expression and infiltration of cytotoxic T cells in the tumour microenvironment in patients with previously untreated metastatic or locally advanced esophagogastric cancer.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair.
Ooki A, Osumi H, Yoshino K, Yamaguchi K. · · 2024 · cited 37× · PMID 38922524 · DOI 10.1007/s10120-024-01523-4
Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers.
Amato M, Franco R, Facchini G, Addeo R, et al · · 2022 · cited 32× · PMID 35955855 · DOI 10.3390/ijms23158726
Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy.
Wu H, Ma W, Jiang C, Li N, et al · · 2023 · cited 23× · PMID 37667098 · DOI 10.1245/s10434-023-14103-0
Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors.
Ciernikova S, Sevcikova A, Novisedlakova M, Mego M. · · 2024 · cited 9× · PMID 39766170 · DOI 10.3390/cancers16244271
Molecular Mechanism for Malignant Progression of Gastric Cancer Within the Tumor Microenvironment.
Matsuoka T, Yashiro M. · · 2024 · cited 9× · PMID 39519285 · DOI 10.3390/ijms252111735
Pharmacomicrobiomics of cell-cycle specific anti-cancer drugs - is it a new perspective for personalized treatment of cancer patients?
Kaźmierczak-Siedlecka K, Bulman N, Ulasiński P, Sobocki BK, et al · · 2023 · cited 7× · PMID 37985748 · DOI 10.1080/19490976.2023.2281017

Verify or expand the search:

Other trials of Capecitabine

Trials testing the same drug.

NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07494448 — Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT06622057 — D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer · Phase 3 · not yet recruiting
NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting

Other recruiting trials for Gastric Adenocarcinoma

Currently open trials in the same condition.

NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
NCT07522320 — Costs of Opportunistic Upper Gastrointestinal Endoscopy and the Economic Burden of Gastric Cancer Management · active not recruiting
NCT07182149 — A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors · Phase 1 · recruiting
NCT07001748 — Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G · Phase 2, PHASE3 · recruiting
NCT07103668 — A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients · Phase 3 · recruiting

Other Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials

Trials by the same sponsor.

NCT07301021 — Velopharyngeal Insufficiency After Maxillomandibular Advancement Osteotomy in Obstructive Sleep Apnea Patients · not yet recruiting
NCT07359482 — sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 · Phase 3 · not yet recruiting
NCT07457957 — Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents · NA · not yet recruiting
NCT06909045 — Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease · NA · recruiting
NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05177133 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Last refreshed: 2 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05177133.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing